EGFR and colorectal carcinoma: The primary endpoint of our study was to demonstrate the EFGR expression on colorectal adenomas, and that is the reason why we used the clone 113 anti-EGFR that had yet been reported as very sensitive for EGFR expression in CRC [10, 11].